Oral cladribine for generalized myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests a new oral medication (cladribine) to see if it can reduce muscle weakness and daily symptoms in people with generalized myasthenia gravis. It compares the drug to a placebo (a pill with no active medicine) to check safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have generalized myasthenia gravis (muscle weakness not just in the eyes).
- Your symptoms are moderate to severe, scoring at least 6 on a standard daily-activity questionnaire.
- You have not taken cladribine before and are not currently on certain immunosuppressants (like azathioprine, mycophenolate, or methotrexate) or have stopped them recently.
- You have no active infections (like tuberculosis, serious viral/bacterial/fungal) and have not had a myasthenic crisis in the last year.
- You weigh at least 40 kg (about 88 pounds) and have not had a thymectomy (thymus removal) in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called SHR-2173, given as an injection, for people with generalized myasthenia gravis. It aims to see if the drug can improve muscle strength and daily function.
This trial tests a new drug called B007 for people with generalized myasthenia gravis who have specific antibodies and moderate to severe muscle weakness. It aims to see if the drug can improve daily activities and reduce symptoms.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests an investigational drug called IMVT-1402 to see if it improves symptoms in people with generalized myasthenia gravis (gMG). If you have mild to severe gMG and are looking for new treatment options, this study may be a fit.
This Phase 3 study tests nipocalimab, a medication given by infusion (and in some groups by injections under the skin), to improve symptoms in adults with generalized myasthenia gravis (MG). It may help reduce weakness in daily activities, especially if you meet specific symptom and safety criteria.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.